Ashley Zimmerman
Family · Braselton, GANPI 1407140999
Payments from drug & device makers
Across 213 payments — averaging $17.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- UCB, Inc.$482
- Argenx US, Inc.$218
- SK Life Science, Inc.$191
- Pfizer$149
- Neurelis, Inc.$144
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,790100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 112 | $1,454 |
| UCB, Inc. | 17 | $482 |
| Argenx US, Inc. | 9 | $218 |
| SK Life Science, Inc. | 6 | $191 |
| Pfizer | 8 | $149 |
| Neurelis, Inc. | 5 | $144 |
| Lundbeck LLC | 5 | $125 |
| Lilly USA, LLC | 6 | $101 |
| Biogen | 4 | $90 |
| Kyowa Kirin, Inc. | 5 | $77 |
| Kedrion Biopharma, Inc. | 3 | $71 |
| Novartis | 4 | $69 |
| Amneal Pharmaceuticals LLC | 4 | $67 |
| Acadia Pharmaceuticals Inc | 3 | $66 |
| Teva Pharmaceuticals USA, Inc. | 3 | $59 |
| Otsuka America Pharmaceutical, Inc. | 2 | $53 |
| Eisai Inc. | 2 | $46 |
| Corium, LLC | 2 | $46 |
| Jazz Pharmaceuticals Inc. | 2 | $39 |
| Amgen | 1 | $28 |
| Neurocrine Biosciences, Inc. | 1 | $26 |
| Catalyst Pharmaceuticals, Inc. | 1 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Johnson & Johnson | 1 | $23 |
| Bristol Myers Squibb | 1 | $22 |
| Astellas Pharma US Inc | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| Medline Industries LP | 1 | $19 |
| AstraZeneca | 1 | $17 |
| Genentech USA, Inc. | 1 | $17 |
How this compares
$3,790 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 15 | $156,556 |
| CopaxoneGlatiramer Acetate | 12 | $68,861 |
| Aimovig AutoinjectorErenumab-Aooe | 84 | $67,190 |
| BotoxOnabotulinumtoxina | 47 | $60,041 |
| Nurtec OdtRimegepant Sulfate | 25 | $46,343 |
| UbrelvyUbrogepant | 34 | $35,652 |
| VimpatLacosamide | 12 | $15,749 |
| Emgality PenGalcanezumab-Gnlm | 18 | $12,702 |
| Lamictal XrLamotrigine | 12 | $11,325 |
| Glatiramer Acetate | 11 | $9,622 |
| Tegretol XrCarbamazepine | 12 | $7,486 |
| Lamotrigine ErLamotrigine | 19 | $6,751 |
| Levetiracetam | 213 | $5,759 |
| Primidone | 137 | $4,813 |
| Eletriptan HbrEletriptan Hydrobromide | 12 | $4,686 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Copaxone | $59 | $225,41727 claims |
| AbbVieBotox, Ubrelvy | $1,454 | $95,69381 claims |
| PfizerNurtec Odt, Dilantin | $149 | $50,58746 claims |
| UCB, Inc.Vimpat | $482 | $15,74912 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $67 | $2,61115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.
Other family in Braselton
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.